Rituximab,used in the treatment of rheumatoid arthritis,depletes _____ through a process involving the cross-linking of _____ on the surface of NK cells and the induction of antibody-dependent cell-mediated cytotoxicity.

Question

Quizplus · Accepted Answer

Rituximab is a monoclonal antibody that targets CD20, a protein primarily found on the surface of B cells. It depletes B cells through a mechanism that involves the cross-linking of FcγRIII (CD16) on the surface of natural killer (NK) cells, leading to the induction of antibody-dependent cell-mediated cytotoxicity (ADCC). This process results in the destruction of B cells, which are implicated in the pathogenesis of rheumatoid arthritis and other autoimmune diseases.

Rituximab,used in the Treatment of Rheumatoid Arthritis,depletes _____ Through a Process